[go: up one dir, main page]

EA201791918A1 - Модификация белков клеток-хозяев - Google Patents

Модификация белков клеток-хозяев

Info

Publication number
EA201791918A1
EA201791918A1 EA201791918A EA201791918A EA201791918A1 EA 201791918 A1 EA201791918 A1 EA 201791918A1 EA 201791918 A EA201791918 A EA 201791918A EA 201791918 A EA201791918 A EA 201791918A EA 201791918 A1 EA201791918 A1 EA 201791918A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proteins
owners
modification
cell
proposed
Prior art date
Application number
EA201791918A
Other languages
English (en)
Inventor
Дарья Бураков
Майкл Горен
Ган Чэнь
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201791918A1 publication Critical patent/EA201791918A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предлагаются композиции и способы для сконструированных клеточных линий и экспрессионных систем, которые позволяют экспрессировать рекомбинантные белки в эукариотических клетках и облегчают их выделение. Также предлагаются клеточные экспрессирующие системы, способные экспрессировать белок, представляющий интерес, по существу, свободный от связанного белка клетки-хозяина.
EA201791918A 2015-02-27 2016-02-26 Модификация белков клеток-хозяев EA201791918A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126213P 2015-02-27 2015-02-27
US201662298869P 2016-02-23 2016-02-23
PCT/US2016/019915 WO2016138467A1 (en) 2015-02-27 2016-02-26 Host cell protein modification

Publications (1)

Publication Number Publication Date
EA201791918A1 true EA201791918A1 (ru) 2017-12-29

Family

ID=55538620

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791918A EA201791918A1 (ru) 2015-02-27 2016-02-26 Модификация белков клеток-хозяев

Country Status (20)

Country Link
US (1) US20160251411A1 (ru)
EP (1) EP3262168B1 (ru)
JP (1) JP6751402B2 (ru)
KR (1) KR20170120126A (ru)
CN (1) CN107406831A (ru)
AU (1) AU2016224988A1 (ru)
BR (1) BR112017018149A2 (ru)
CA (1) CA2976669A1 (ru)
DK (1) DK3262168T3 (ru)
EA (1) EA201791918A1 (ru)
ES (1) ES2751670T3 (ru)
HK (1) HK1248272A1 (ru)
HU (1) HUE045862T2 (ru)
IL (1) IL253863A0 (ru)
MX (1) MX2017011012A (ru)
MY (1) MY180896A (ru)
SG (1) SG11201706335TA (ru)
TW (1) TW201702380A (ru)
WO (1) WO2016138467A1 (ru)
ZA (1) ZA201705712B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039499A1 (en) * 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
CA3043487A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
WO2019036626A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS
US12178874B2 (en) 2017-11-20 2024-12-31 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
JP2021521873A (ja) * 2018-05-04 2021-08-30 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ 改変された宿主細胞タンパク質プロファイルを有する操作された細胞
US20210238222A1 (en) * 2018-05-04 2021-08-05 Sigma-Aldrich Co. Llc Producing recombinant proteins with reduced levels of host cell proteins
CA3130457A1 (en) * 2019-03-05 2020-09-10 Regeneron Pharmaceuticals, Inc. Human serum albumin in formulations
KR20220061107A (ko) * 2019-09-12 2022-05-12 론자 리미티드 지질용해 활성의 검출을 위한 조성물, 방법 및 키트
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
WO2024178239A1 (en) * 2023-02-22 2024-08-29 Shattuck Labs, Inc. Engineered cell lines and uses thereof
EP4438620A1 (en) 2023-03-30 2024-10-02 Sartorius Stedim Cellca GmbH Cho cells with optimized host cell protein profile
EP4438622A1 (en) 2023-03-30 2024-10-02 Sartorius Stedim Cellca GmbH Cho cells with optimized ecm profile

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4091119B2 (ja) * 1996-09-19 2008-05-28 ノボザイムス アクティーゼルスカブ 新規な宿主細胞およびタンパク質生産方法
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
GB201000587D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
JP2014522868A (ja) * 2011-07-29 2014-09-08 イレブン・バイオセラピユーテイクス・インコーポレイテツド 精製タンパク質
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP6546178B2 (ja) * 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
AU2014318615B2 (en) 2013-09-13 2020-03-12 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
WO2015095568A1 (en) 2013-12-18 2015-06-25 Kelvin Lee Reduction of lipase activity in product formulations

Also Published As

Publication number Publication date
JP2018506295A (ja) 2018-03-08
CA2976669A1 (en) 2016-09-01
ES2751670T3 (es) 2020-04-01
BR112017018149A2 (pt) 2018-04-10
MY180896A (en) 2020-12-11
JP6751402B2 (ja) 2020-09-02
DK3262168T3 (da) 2019-10-07
HUE045862T2 (hu) 2020-01-28
IL253863A0 (en) 2017-09-28
KR20170120126A (ko) 2017-10-30
ZA201705712B (en) 2020-01-29
WO2016138467A1 (en) 2016-09-01
MX2017011012A (es) 2017-10-20
US20160251411A1 (en) 2016-09-01
EP3262168B1 (en) 2019-08-21
CN107406831A (zh) 2017-11-28
SG11201706335TA (en) 2017-09-28
TW201702380A (zh) 2017-01-16
EP3262168A1 (en) 2018-01-03
AU2016224988A1 (en) 2017-09-07
HK1248272A1 (zh) 2018-10-12

Similar Documents

Publication Publication Date Title
EA201791918A1 (ru) Модификация белков клеток-хозяев
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
MX2022006513A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
BR112019012343A2 (pt) anticorpos il-11ra
MX382518B (es) Antigenos de citomegalovirus y su uso.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
MY191944A (en) Binding proteins and methods of use thereof
IL286776A (en) Compositions and methods for preparing t cell compositions and uses thereof
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX356162B (es) Sistema de expresion y secrecion.
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
HK1258313A1 (zh) 建立化学诱导的二聚化蛋白体系以调节细胞事件的方法
TR201900638T4 (tr) Anti̇-cd52 anti̇korlari.
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
NZ731491A (en) Cd83 binding proteins and uses thereof
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX2015012281A (es) Proteinas de union a tnf mejoradas.
DK3277818T3 (da) Brug af vitaminer og vitaminstofskiftegener og -proteiner til produktion af rekombinant protein i pattedyrsceller
IL272955A (en) Methods, preparations and cells for the preparation of protein d
MX384990B (es) Selectividad eficaz de proteínas recombinantes.